Kezar Life Sciences Inc reports results for the quarter ended in December - Earnings Summary

Kezar Life Sciences

15/03/2023 11:59

* Kezar Life Sciences Inc  KZR.OQ  reported a quarterly
adjusted
loss of 25 cents​​ per share for the quarter ended in December.
The mean expectation of six analysts for the quarter was for a
loss of 28 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kezar Life Sciences Inc's reported EPS for the quarter was
a
loss of 25 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Kezar Life Sciences Inc shares had fallen by 26.4% this
quarter.
    * The company reported a quarterly loss of $18.18 million.
    * Wall Street's median 12-month price target for Kezar Life
Sciences Inc is $17.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 15 at 11:59 a.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.28          -0.25          Beat
 Sep. 30 2022      -0.27          -0.25          Beat
 Jun. 30 2022      -0.27          -0.25          Beat
 Mar. 31 2022      -0.28          -0.26          Beat